Ariceum Therapeutics develops radiopharmaceuticals using lutetium-177 and actinium-225 to target aggressive cancers with precision therapy. (read full article...)
Ariceum filed for “provisional insolvency” at the Berlin-Charlottenburg District Court in early January 2026.
Is there any new information, or what is the background to this positive article?
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.